Back to top

Arrowhead completes enrollment in Phase 3 YOSEMITE trial

Arrowhead (ARWR) Pharmaceuticals announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: